(Q34133677)

31 July 2017

1 reference

title

Scientists and clinicians test their metal-back to the future with platinum compounds (English)

1 reference

31 July 2017

1 reference

2

Paul R Harnett

1 reference

31 July 2017

Anna deFazio

3

0 references

author name string

Alexander D Guminski

series ordinal

1

1 reference

31 July 2017

1 May 2002

1 reference

Lancet Oncology Commission

31 July 2017

1 reference

31 July 2017

3

1 reference

31 July 2017

312-318

1 reference

31 July 2017

5

1 reference

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Liposomes as carriers of antitumor agents: toward a clinical reality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

The Mechanism of Action of Antitumor Platinum Compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Biological properties of cis- and trans- dichlorodiammineplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Selective modification of glutathione metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Mechanisms of cisplatin (cis-diamminodichloroplatinum II)-induced cytotoxicity and genotoxicity in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Cellular accumulation of the anticancer agent cisplatin: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

DNA mismatch correction in a defined system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Mechanisms of DNA excision repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

DNA double strand break repair in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

1 reference

7 January 2021

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Transcription-coupled repair and human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Disruption of DNA-PK in Ku80 mutant xrs-6 and the implications in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Quality control by DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Lessons learned from BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

In search of the tumour-suppressor functions of BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

The p53 tumor suppressor gene: from molecular biology to clinical investigation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Interactions of mammalian proteins with cisplatin-damaged DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Recombination factors of Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Mechanisms and biological effects of mismatch repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Eukaryotic polymerases iota and zeta act sequentially to bypass DNA lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Low fidelity DNA synthesis by human DNA polymerase-eta.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase β

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Novel functional interactions between nucleotide excision DNA repair proteins influencing the enzymatic activities of TFIIH, XPG, and ERCC1-XPF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Cancer cells, chemotherapy and gene clusters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

A gene expression database for the molecular pharmacology of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Creation of human tumour cells with defined genetic elements

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Telomere loss in cells treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900733-7

7 January 2021

10.1016/S1470-2045(02)00733-7

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

12067809